Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.63 |
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22919876 | 0.91 | MAPK14 (0.52) | MAPK14BRAFKDRMETFLT1 | |
| SCHEMBL16895218 | 0.87 | MAPK14 (0.53) | MAPK14BRAFCYP17A1MAPK13KDR | |
| SCHEMBL30729902 | 0.87 | MAPK14 (0.53) | MAPK14BRAFCYP17A1MAPK13KDR | |
| SCHEMBL2865557 | 0.87 | ABL1 (0.52) | MAPK14BRAFCYP17A1MAPK13KDR | |
| SCHEMBL24037398 | 0.86 | MAPK14 (0.48) | MAPK14BRAFCYP17A1MAPK13KDR | |
| SCHEMBL1136971 | 0.86 | MAPK14 (0.65) | MAPK14BRAFMAPK13KDRMET | |
| SCHEMBL29834707 | 0.85 | ABL1 (0.51) | MAPK14BRAFCYP17A1MAPK13KDR | |
| SCHEMBL107558 | 0.85 | MET (0.48) | MAPK14BRAFCYP17A1KDRMET | |
| SCHEMBL29834756 | 0.85 | ABL1 (0.53) | MAPK14BRAFCYP17A1MAPK13KDR | |
| SCHEMBL30729882 | 0.84 | MAPK14 (0.46) | MAPK14BRAFCYP17A1MAPK13KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2248810-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-11-10 | — | — | EP | disclosed |
| EP-2248810-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009104520-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311972-A1 | METHOD FOR PRODUCING PHENOXYPYRIDINE DERIVATIVE | TET2, QDPR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPK14 1986/4885BRAF 1722/4885CYP17A1 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.